There are five probiotic strains in For every day EXTRA Strength - two Lactobacillus strains and three Bifidobacterium strains. All of them have been involved extensively in research, and there are impressive clinical trials on the finished product formula, demonstrating their potential to help protect the gut during antibiotic use. There is one strain in this formula that stands out as the champion -L. acidophilus NCFM®. There are over 45 clinical trials on this strain, covering a wide variety of different health conditions, which has earned it a place as one of the most celebrated strains in the OptiBac Probiotics range. The strain name NCFM is taken from the 'North Carolina Food Microbiology' research laboratory where this strain was first identified in the 1970s. In the many years since then, the L. acidophilus NCFM® strain has been studied in numerous clinical studies, some of which are discussed below.

Recent research on For every day EXTRA Strength

For every day EXTRA Strength shown to minimise antibiotic disturbance - A study investigated the effect of probiotics on antibiotic induced gut microbiota to determine whether a probiotic formula, containing all of the strains found in 'For every day EXTRA Strength' (formerly known as 'For daily wellbeing EXTRA Strength'), minimised the disturbance of faecal microbiota. The study, conducted over a 48 day period, observed 51 healthy subjects administered with amoxicillin/clavulanate and randomised to concomitantly receive either a probiotic formula or a placebo. Prior to antibiotic therapy the subjects gave three faecal samples to determine their baseline microbiota when healthy. Four faecal samples were also taken post antibiotic therapy for comparison. The results showed that the most common antibiotic disturbance was a relative increase in Clostridium, Eubacterium, Bacteroides and Enterobacteraceae. More interestingly, those subjects that took the probiotic formula showed less disturbance in their faecal microbiota and promoted a more rapid return to their pre-antibiotic baseline state.

Source: Engelbrektson, A. et al. (2009) Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. Journal of Medical Microbiology. Vol. 58 pp. 663-670

Clinical Trials on all probiotic strains in For every day EXTRA Strength

Engelbrektson, AL et al. (2009) Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol 58: 663-670.

Clinical Trials on Lactobacillus acidophilus NCFM®

Faber, SM. (2000) Treatment of abnormal gut flora improves symptoms in patients with irritable bowel syndrome. Am J Gastroenterol 95(9):2533.

Sui, J et al. (2002) 16S ribosomal DNA analysis of the faecal lactobacilli composition of human subjects consuming a probiotic strain Lactobacillus acidophilus NCFM®. J Appl Microbiol 93:907-912.

Ouwehand, AC et al. (2009) Influence of a combination of Lactobacillus acidophilus NCFM® and lactitol on healthy elderly: intestinal and immune parameters. British Journal of Nutrition, Vol. 101, pp. 367-375

Engelbrektson, AL et al. (2005) Analysis of treatment effects on the microbial ecology of the gastrointestinal tract. PhD Thesis, California Polytechnic State University, San Luis Obispo, USA.

Varcoe, J et al. (2002) Variable response to exogenous Lactobacillus acidophilus NCFM® consumed in different delivery vehicles. J Appl Microbiol 93:900-906.

Crowell, DC. (1998) Microbial analysis of human intestinal flora after feeding Lactobacillus acidophilus. M.S. Thesis, North Carolina State Univ, Raleigh.

Gilliland, SW et al. (1978) Influence of consuming nonfermented milk containing Lactobacillus acidophilus on fecal flora of healthy males. J Dairy Sci 61:1-10.

Gilliland, SE et al. (1975) Detection of Lactobacillus acidophilus in feces of humans, pigs, and chickens. Appl Microbiol; 30(4):541-545.

Ringel-Kulka (2014) Lactobacillus acidophilus NCFM® affects colonic mucosal opioid receptor expression in patients with functional abdominal pain - a randomised clinical study. Ailment. Pharmacol. Ther. 40, 2. 200-7.

Ringel-Kulka summary: Studies have suggested that the reason this strain seems to have such a relieving effect on the discomfort experienced by those suffering with IBS, is because it can communicate with cells in the gut and modulate the signals involved in creating spasms, to pacify the distention and pain. This has been demonstrated in a double-blind, randomised, controlled clinical trial, where 20 IBS sufferers took either L. acidophilus NCFM® alone or a combination of L. acidophilus NCFM® and B. lactis Bi-07 (also in 'For every day EXTRA Strength') at a dose of 20 billion twice a day for 3 weeks. Samples of gut tissue from each participant were examined, to look at the cell-signalling pathways involved in IBS symptoms, such as the stimulation of opioid receptors. Both groups felt they experienced an improvement in IBS symptoms but the L. acidophilus NCFM® alone group also had a notable decrease in the pain perception signalling pathways showing up in their tissue samples.

Mustapha (1997) Improvement of lactose digestion by humans following ingestion of unfermented acidophilus milk: influence of bile sensitivity, lactose transport, and acid tolerance of Lactobacillus acidophilus. J Dairy Sci. 80, 8. 1537-45.

See our probiotic database for more research on L. acidophilus NCFM®.

Clinical Trials on Lactobacillus acidophilus NCFM® with Bifidobacterium lactis Bl-04

Ouewhand, AC et al. (2009) Specific probiotics alleviate allergic rhinitis during the birch pollen season. World Journal of Gastronenterol; Vol. 15, pp. 3261 - 3268

Ouewhand summary: 47 children with hay fever (triggered by birch tree pollen) took a combination of L. acidophilus NCFM® andB. lactis Bl-04 (5 billion/day), or placebo, during the spring months in a randomised trial. Those taking the two strain combination had significantly reduced presence of eosinophils (a type of white blood cell which is involved in controlling allergies) in the nose area, compared to the placebo group, at the height of the hay fever season. This correlated with what the participants reported - those on the two-strain probiotic had reduced blocked and runny noses, compared to those in the placebo group.

Clinical Trials on Lactobacillus acidophilus NCFM® with Bifidobacterium lactis Bi-07

Leyer GJ, et al. (2009) Probiotic effects on cold and influenza-like symptom incidences and duration in children. Official Journal of the American Academy of Pediatrics; Vol. 124, pp. 172-179

Ringel, Y. et al. (2008) Probiotic bacteria Lactobacillus acidophilus NCFM® and Bifidobacterium lactis Bi-07 improve symptoms of bloating in patients with function bowel disorders (FBD). Gastoenterology; Vol 134(4 Suppl. 1):A549

Clinical Trials on Bifidobacterium lactis Bi-07

Lehtinen summary: A double-blind, randomised, placebo-controlled study, involving 37 elderly adults found that daily supplementation withB. lactis Bi-07 had beneficial effects on the immune function of the participants. Study participants showed increased phagocytic activity of monocytes and granulocytes - immune cells that "eat" pathogenic bacteria and infected cells in the body and are one of the body's mechanisms that help prevent illness and infection.

Click on this link for more research on B. lactis Bi-07.

Clinical Trials on Bifidobacterium lactis Bl-04

Paineau, D. et al. (2008). Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomised, controlled trial. FEMS Immunology and Medical Microbiology, Vol. 53 (1), pp. 107-13

Click on this link for more research on B. lactis BI-04.

Clinical Trials on Lactobacillus acidophilus NCFM® with Bifidobacterium lactis Bi-07 and Bifidobacterium lactis Bl-04

West (2014) Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy, physically active individuals. Clinical Nutrition. 33, 4. pp. 581-7
West summary: This double-blind, randomised, placebo-controlled study took place in Australia, which involved 465 participants who exercised regularly. Although exercise is generally considered to be good for us, significant exercise can put a strain on the immune system, and when this happens we can experience more coughs and colds.

In this trial there were three groups - Group 1 took B. lactis Bl-04 (2 billion per day), Group 2 took a combination of L. acidophilus NCFM® & B. lactis Bi-07 (10 billion per day) and Group 3 took placebo. Over the five months of the trial those in the B. lactis Bl-04 had 27% less risk of getting a cough or cold (upper respiratory tract infection URTI) compared to the placebo group.
Those in the L. acidophilus NCFM® & B. lactis Bi-07 group also had decreased risk of a cough or cold but this wasn't as significant as in the B. lactis Bl-04 group. The graph (right) clearly shows that those taking the probiotics had fewer episodes of sickness, and they fended sickness off for longer, compared to those in the placebo group.